NCT00839826View on ClinicalTrials.gov

ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

641

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

November 30, 2003

Study Completion Date

November 30, 2003

Conditions
ThromboembolismPrevention
Interventions
DRUG

Rivaroxaban (BAY59-7939)

2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial

DRUG

Enoxaparin

40 mg bid

Trial Locations (41)

1090

Brussels

1220

Vienna

2700

Wiener Neustadt

2730

Herlev

2900

Hellerup

4010

Linz

4500

Huy

7331

Baudour

8600

Silkeborg

9000

Ghent

14165

Berlin

31096

Haifa

52621

Tel Litwinsky

54037

Nancy

59037

Lille

60528

Frankfurt am Main

64239

Tel Aviv

65929

Frankfurt am Main

70300

Ẕerifin

79618

Rheinfelden

80030

Amiens

82467

Garmisch-Partenkirchen

90766

Fürth

DK-2970

Hørsholm

01307

Dresden

3818 ES

Amersfoort

8025 AB

Zwolle

NO-3675

Notodden

0440

Oslo

NO-3660

Rjukan

15-276

Bialystok

80-742

Gdansk

31-826

Krakow

91-425

Lodz

20-090

Lublin

20-718

Lublin

00-909

Warsaw

416 85

Gothenburg

551 85

Jönköping

442 83

Kungälv

SE5 9RS

London

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00839826 - ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial | Biotech Hunter | Biotech Hunter